EE200000358A - 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid - Google Patents

2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid

Info

Publication number
EE200000358A
EE200000358A EEP200000358A EEP200000358A EE200000358A EE 200000358 A EE200000358 A EE 200000358A EE P200000358 A EEP200000358 A EE P200000358A EE P200000358 A EEP200000358 A EE P200000358A EE 200000358 A EE200000358 A EE 200000358A
Authority
EE
Estonia
Prior art keywords
purin
tetrahydrofuran
diol derivatives
diol
derivatives
Prior art date
Application number
EEP200000358A
Other languages
English (en)
Estonian (et)
Inventor
Peter Charles Cousins Richard
Victoria Geden Joanna
Chan Chuen
Mary Cook Caroline
Cox Brian
Joan Dyke Hazel
Ellis Frank
Swanson Stephen
Bays David
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200000358(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9803169.3A external-priority patent/GB9803169D0/en
Priority claimed from GBGB9813533.8A external-priority patent/GB9813533D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000358A publication Critical patent/EE200000358A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200000358A 1998-02-14 1999-02-12 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid EE200000358A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9803169.3A GB9803169D0 (en) 1998-02-14 1998-02-14 Chemical compounds
GBGB9813533.8A GB9813533D0 (en) 1998-06-23 1998-06-23 Chemical compounds
PCT/EP1999/000915 WO1999041267A1 (en) 1998-02-14 1999-02-12 2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives

Publications (1)

Publication Number Publication Date
EE200000358A true EE200000358A (et) 2001-10-15

Family

ID=26313119

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000358A EE200000358A (et) 1998-02-14 1999-02-12 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid

Country Status (32)

Country Link
US (1) US6610665B1 (hr)
EP (1) EP1056759B1 (hr)
JP (1) JP2002503669A (hr)
KR (1) KR20010082512A (hr)
AP (1) AP2000001881A0 (hr)
AR (1) AR017457A1 (hr)
AT (1) ATE223429T1 (hr)
AU (1) AU757156B2 (hr)
BR (1) BR9907886A (hr)
CA (1) CA2319009A1 (hr)
CO (1) CO4990969A1 (hr)
DE (1) DE69902758T2 (hr)
DK (1) DK1056759T3 (hr)
EA (1) EA200000759A1 (hr)
EE (1) EE200000358A (hr)
ES (1) ES2183516T3 (hr)
HK (1) HK1032062A1 (hr)
HR (1) HRP20000538A2 (hr)
HU (1) HUP0100702A3 (hr)
IL (1) IL137402A0 (hr)
IS (1) IS5576A (hr)
MA (1) MA27121A1 (hr)
NO (1) NO20004045L (hr)
NZ (1) NZ505812A (hr)
PE (1) PE20000270A1 (hr)
PL (1) PL342396A1 (hr)
PT (1) PT1056759E (hr)
SK (1) SK12002000A3 (hr)
SV (1) SV1999000016A (hr)
TR (1) TR200002355T2 (hr)
WO (1) WO1999041267A1 (hr)
YU (1) YU50800A (hr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) * 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AR017457A1 (es) * 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CA2335809A1 (en) 1998-06-23 1999-12-29 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
GB9930075D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
EP1434782A2 (en) 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
SG155182A1 (en) 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
BR112012003709B1 (pt) 2009-08-17 2021-05-18 Intellikine Llc compostos heterocíclicos e usos dos mesmos
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414193D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AR017457A1 (es) * 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
CA2335809A1 (en) * 1998-06-23 1999-12-29 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Also Published As

Publication number Publication date
NO20004045D0 (no) 2000-08-11
NO20004045L (no) 2000-08-11
EA200000759A1 (ru) 2001-04-23
HUP0100702A2 (hu) 2002-01-28
NZ505812A (en) 2002-03-01
EP1056759A1 (en) 2000-12-06
PE20000270A1 (es) 2000-05-20
AR017457A1 (es) 2001-09-05
AU757156B2 (en) 2003-02-06
DK1056759T3 (da) 2003-01-06
ES2183516T3 (es) 2003-03-16
PT1056759E (pt) 2003-01-31
PL342396A1 (en) 2001-06-04
DE69902758T2 (de) 2003-05-15
IS5576A (is) 2000-07-25
WO1999041267A1 (en) 1999-08-19
SV1999000016A (es) 1999-10-27
AU2623599A (en) 1999-08-30
SK12002000A3 (sk) 2001-07-10
BR9907886A (pt) 2000-10-17
CO4990969A1 (es) 2000-12-26
ATE223429T1 (de) 2002-09-15
JP2002503669A (ja) 2002-02-05
KR20010082512A (ko) 2001-08-30
EP1056759B1 (en) 2002-09-04
HRP20000538A2 (en) 2000-12-31
US6610665B1 (en) 2003-08-26
IL137402A0 (en) 2001-07-24
HK1032062A1 (en) 2001-07-06
DE69902758D1 (de) 2002-10-10
TR200002355T2 (tr) 2000-11-21
CA2319009A1 (en) 1999-08-19
AP2000001881A0 (en) 2000-09-30
MA27121A1 (fr) 2005-01-03
YU50800A (sh) 2003-04-30
HUP0100702A3 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
EE200000768A (et) 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid
EE200000441A (et) 2-(puriin-9-üül) tetrahüdrofuraan-3,4-diooli derivaadid
EE200000358A (et) 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid
EE200000764A (et) 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid
EE9900312A (et) 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid
DK1117669T3 (da) Antiviruspurinderivater
DE69920697D1 (de) Adenosinderivate
SI1056759T1 (en) 2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives
GB9909482D0 (en) 2-(Purin-9-yl)-tetahydrofuran-3,4-diol derivatives
ZA99689B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.
ZA991154B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.